Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) news covers developments at a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches and nanotechnology platforms. As a dual-listed issuer on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix regularly publishes updates that are relevant to investors following oncology-focused biotechnology and pharmaceutical preparation manufacturing.
Company news frequently highlights progress in the JNJ-1900 (NBTXR3) clinical program, including updates on the global Phase 3 NANORAY-312 study in locally advanced head and neck squamous cell cancers and Phase 1 and Phase 2 studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Releases may also describe regulatory designations, collaboration milestones with Janssen Pharmaceutica NV, and the transfer of sponsorship and operational control of key trials.
Another recurring theme in Nanobiotix news is the Curadigm Nanoprimer platform. The company reports on new patent applications, preclinical in vivo data, and Chemistry, Manufacturing, and Controls (CMC) activities, as well as material transfer agreements with biotechnology and pharmaceutical partners evaluating Nanoprimer combinations with intravenously administered therapeutics.
Investors can also find announcements related to capital markets activity, such as royalty-based financing agreements with HealthCare Royalty (HCRx), inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, and periodic disclosures on shares outstanding and voting rights under French regulations. In addition, Nanobiotix issues notices about participation in investor and healthcare conferences, where management presents the company’s strategy and clinical pipeline.
By following NBTX news, readers can track clinical, financial, and strategic updates that shape the company’s development trajectory and its work in oncology, drug bioavailability and biodistribution, and central nervous system disorder applications.
NANOBIOTIX (NASDAQ:NBTX) entered a royalty monetization agreement with HealthCare Royalty (HCRx) providing up to $71 million in non-dilutive capital to fund development of JNJ-1900 (NBTXR3) and next‑wave nanotherapeutics. The company will receive $50 million upfront and may receive an additional $21 million one year post‑closing subject to conditions. Repayment is sourced from a portion of royalties and milestones on the first $1 billion of net sales with a capped return of ~$124M if repaid by end of 2030 (1.75x) or ~$178M thereafter (2.5x).
Following the cap, a reduced royalty tail (≤$14.9M/yr) applies for up to 10 years after first US commercial sale. The deal transfers receivables to a French law trust and, assuming full drawdown, extends cash runway into early 2028.
NANOBIOTIX (NASDAQ:NBTX) announced completion of the transfer of sponsorship for the NANORAY-312 Phase 3 head and neck cancer trial (initiated 3Q2024) in the majority of regions and transfer of full operational control to Johnson & Johnson.
Following Nanobiotix's review of the latest information, the Company now estimates that NANORAY-312 interim data will be analyzed and reported in 1H2027 after the requisite number of events and last patient recruitment. Future guidance for NANORAY-312 and other JNJ-1900 (NBTXR3) studies sponsored by J&J will be provided by J&J. Nanobiotix will continue to update on Nanobiotix-sponsored studies and MD Anderson-sponsored trials.
NanoBioTix (Nasdaq: NBTX) provided its voting rights and share capital update dated October 15, 2025. The company reports 48,237,471 shares outstanding (as of September 30, 2025) and a total theoretical number of voting rights of 50,318,257 with 50,296,139 exercisable voting rights. Markets: Euronext Paris (Compartment B) and NasdaqEuronext. ISIN: FR0011341205. This notice fulfills disclosure requirements under French commercial and AMF rules regarding the number of shares and voting rights.
Nanobiotix (NASDAQ: NBTX) has announced promising first data from a Phase 1 study of JNJ-1900 (NBTXR3) in patients with locally advanced esophageal adenocarcinoma. The study, conducted at MD Anderson Cancer Center, demonstrated an 85% disease control rate and 69% objective response rate among 13 patients.
The treatment, combining JNJ-1900 with chemoradiation, showed strong safety profile and confirmed injection feasibility. Key outcomes include 6 complete responses and 3 partial responses. Of 6 patients who underwent surgery, 2 achieved pathological complete response and 4 showed major pathologic response. The recommended Phase 2 dose was established at 33% of gross tumor volume.
The study continues with recruitment of 17 additional patients, exploring both photon and proton chemoradiation combinations.
Nanobiotix (NASDAQ: NBTX) reported its H1 2025 financial results and business updates, highlighting significant progress in its clinical development program for JNJ-1900 (NBTXR3). The company's revenue increased to €26.6 million, up from €9.3 million in H1 2024, primarily due to a €21.2 million non-cash revenue impact from the J&J agreement amendment.
R&D expenses decreased to €14.5 million from €22.0 million, while net loss improved to €5.4 million from €21.9 million year-over-year. Cash position stood at €28.8 million as of June 30, 2025, expected to fund operations into mid-2026. However, the company noted material uncertainty about its going concern status and is in active discussions for non-dilutive financing to extend its cash runway.
The company achieved several clinical milestones, including the first patient dosing in the CONVERGE study and data announcements from various Phase 1 trials evaluating JNJ-1900 across different cancer types.Nanobiotix (NASDAQ: NBTX) announced updated Phase 1 results for JNJ-1900 (NBTXR3) in combination with anti-PD-1 therapy for head and neck cancer patients. The study showed promising outcomes in both anti-PD-1 naïve and resistant patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC).
Key findings include a 63% disease control rate and 37% objective response rate in anti-PD-1 naïve patients, while resistant patients showed a 74% disease control rate and 32% objective response rate. The treatment demonstrated strong local control with a 95% aggregate disease control rate in injected lesions across all evaluable patients. Median overall survival reached 15.5 months for naïve patients and 11.4 months for resistant patients.
The treatment was well-tolerated among 103 heavily pre-treated patients, with investigators concluding these promising results warrant further exploration in randomized controlled trials.
Nanobiotix (NASDAQ: NBTX) has announced promising new results from a Phase 1 study of JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors for treating primary cutaneous melanoma resistant to anti-PD-1. The study showed a 47.4% objective response rate and 78.9% disease control rate in all lesions per RECIST 1.1.
Key findings include a median Overall Survival of 14.6 months and establishment of the recommended phase 2 dose at 33% of gross tumor volume. The treatment demonstrated a favorable safety profile, with only 5 patients experiencing treatment-related adverse events. Notably, in JNJ-1900 injected & irradiated tumors, researchers observed a 100% disease control rate.
Nanobiotix (NASDAQ:NBTX) has released its monthly update on voting rights and share capital as of August 31, 2025. The company reported 48,236,771 shares outstanding, with 50,337,954 theoretical voting rights and 50,315,836 exercisable voting rights.
This disclosure is made in compliance with French regulatory requirements, as the company is listed on both Euronext Paris and Nasdaq.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management team, including CEO Laurent Levy and CFO Bart van Rhijn, will participate in a fireside chat on Tuesday, September 9th, 2025, at 9:00 am EDT. The presentation will be accessible via webcast on the company's investor relations website, with a replay available after the event.
Nanobiotix (NASDAQ: NBTX) has reported its latest voting rights and share capital status as of July 31, 2025. The company disclosed a total of 48,236,671 shares outstanding, with 50,340,736 theoretical voting rights and 50,318,618 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, with dual listings on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.